‘Encouraging’ results for Noxopharm drug

Sydney biotech Noxopharm says a clinical trial suggests its radiation-sensitising suppository was able to extend the average lifespan of 32 men with terminal prostate cancer.

The men were treated with Veyonda in combination with Novartis’ $6 billion experimental radioactive drug 177Lu-PSMA-617 at St Vincent’s Hospital Sydney after at least two and in most cases three lines of therapy had failed.

They lived an average of 17.1 months despite two-thirds of them having over 20 tumours in their bones and lymph nodes.

Noxopharm chief medical officer Dr Gisela Mautner said the men “normally would have a much shorter survival expectation”.

“These interim results are highly relevant for a patient group that is at the very end of their treatment journey with very limited life expectancy,” she said.

Twenty of the 32 patients had a strong reduction in their PSA levels, an important marker for anti-cancer activity, and many experienced a reduction in severe pain. 

The study is continuing with another 24 men being treated with a higher dose of Veyonda, also in combination with 177Lu-PSMA-617, which is injected intravenously once every six weeks for 36 weeks.

Noxopharm says the twice-daily suppository works by blocking cancer cells from being able to repair DNA damaged by radiation therapy.

“Our belief is that Veyonda works in a way that will provide a worthwhile boost to all radiopharmaceuticals, not just 177Lu-PSMA-617,” executive chairman and chief executive Dr Graham Kelly said.

At 1550  AEDT, Noxopharm shares were up one cent, or 4.4 per cent, to 23.5 cents.


Be the first to comment

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.